Insulet's SECURE-T2D trial demonstrated that Omnipod 5, an automated insulin delivery system, improved type 2 diabetes outcomes and quality of life.
Insulet's SECURE-T2D pivotal trial showed Omnipod 5, an automated insulin delivery system, improved clinical outcomes and quality of life in adults with type 2 diabetes. The study showed a 0.8 percentage point reduction in HbA1c at 13 weeks, with fewer adults reporting diabetes distress. The system also reduced time in hyperglycemia, total daily insulin dose, and increased time in range without increasing time in hypoglycemia.
June 21, 2024
7 Articles